RxDoctor Payments Data

Keith Vrbicky, MD

Obstetrics & Gynecology · Norfolk, NENPI 1477561660

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,214 of the $1,407 with a category attached, or 86.3%. 16 manufacturers reported payments, led by AbbVie at 32.4% of the total. Reporting peaked in 2019 at $603 and has fallen 86.6% since, to $81 in 2025.

$1,407in general payments, 2019–2025

Across 57 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$456
  • Seqirus USA Inc$421
  • Daiichi Sankyo Inc.$133
  • Biohaven Pharmaceuticals, Inc.$61
  • Minerva Surgical, Inc$56
  • Pfizer$49
  • plus $232 from 10 others
$23,657,649in research payments, 2019–2025

Across 1,478 payments — averaging $16,007 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$19.4M
  • Pfizer$2.8M
  • GSK$484K
  • Seqirus USA Inc$435K
  • Johnson & Johnson$129K
  • Exeltis, USA Inc.$82K
  • plus $346K from 10 others

What the payments were for

  • Travel & lodging$16011%
  • Food & beverage$1,21486%
  • Gifts$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,407 in reported general payments places this provider in the 65th percentile of 242 obstetrics & gynecology providers in Nebraska.

See all obstetrics & gynecology providers in Nebraska

Medicare billing

Part B allowed, 2024
$100,554
Medicare patients
495
Services billed
2,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProgesteroneProgesterone, Micronized110$4,513
ArexvyRsvpref3 Antigen/As01e/Pf12$3,376
Levothyroxine Sodium168$1,454
Estradiol30$911
Estradiol (Once Weekly)Estradiol15$872
Risedronate Sodium12$611
Liothyronine Sodium17$540
Pravastatin Sodium12$532
Oxybutynin Chloride ErOxybutynin Chloride24$461
Rosuvastatin Calcium31$449
Simvastatin42$431
Losartan Potassium38$367
Cyproheptadine Hcl20$331
Omeprazole17$291
Venlafaxine Hcl ErVenlafaxine Hcl18$290

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Norfolk

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →